Trilogy Heart Valve System

About JenaValve

JenaValve is a pioneering medical device company that has achieved a first-in-class FDA approval with its Trilogy TAVR system for treating severe aortic regurgitation, a condition previously lacking a dedicated transcatheter solution. The company's core innovation is its locator technology, which provides commissural alignment and secure anchoring without relying on native valve calcification, leading to strong clinical outcomes as demonstrated in the ALIGN-AR pivotal study. Positioned in the large and growing structural heart market, JenaValve has carved out a unique and defensible niche, though it faces competition from large incumbent device companies and the ongoing challenge of market adoption and reimbursement.

About JenaValve

JenaValve is a pioneering medical device company that has achieved a first-in-class FDA approval with its Trilogy TAVR system for treating severe aortic regurgitation, a condition previously lacking a dedicated transcatheter solution. The company's core innovation is its locator technology, which provides commissural alignment and secure anchoring without relying on native valve calcification, leading to strong clinical outcomes as demonstrated in the ALIGN-AR pivotal study. Positioned in the large and growing structural heart market, JenaValve has carved out a unique and defensible niche, though it faces competition from large incumbent device companies and the ongoing challenge of market adoption and reimbursement.

Therapeutic Areas